Gastrointestinal stromal tumor

This early-stage trial tests a radioactive drug (Lu-177 edotreotide) in children aged 2 to 17 with cancers that have a specific marker (SSTR-positive). The goal is to find the right dose and check safety. About 20 children whose cancer has returned or not responded to prior treat…

This expanded access program provides velzatinib (GSK6042981) to patients with gastrointestinal stromal tumors (GIST) that have a KIT mutation and have already tried at least three prior treatments. The program is for people who have no satisfactory alternative, including approve…

This study tests whether adding the immunotherapy drug atezolizumab to the standard drug imatinib can help control advanced gastrointestinal stromal tumors (GIST) that have stopped responding to other treatments. About 110 adults with inoperable or metastatic GIST will be randoml…

This phase 2 trial tests the drug velzatinib in people with advanced gastrointestinal stromal tumors (GIST) that have stopped responding to or cannot tolerate several standard treatments. The study aims to see if velzatinib can shrink or control the tumors and how safe it is. Par…

This study tests a new drug, IDRX-42, against the current standard drug sunitinib in adults with advanced gastrointestinal stromal tumors (GIST) that have spread or can't be removed by surgery and have already been treated with imatinib. About 450 participants will be randomly as…

This study tests a surgery called total pancreatectomy with islet autotransplantation (TPIAT) in 30 adults with certain pancreatic tumors who are at high risk for a dangerous leak after standard surgery. The procedure removes the entire pancreas and transplants the insulin-making…

This phase 2 study tests belzutifan, a daily pill that blocks a protein called HIF-2α, in people with advanced rare cancers like pheochromocytoma/paraganglioma, pancreatic neuroendocrine tumors, VHL disease-associated tumors, and certain other solid tumors. The goal is to see if …

This Phase 2 trial tests an oral drug called BAY 2927088 (sevabertinib) in about 111 adults with advanced solid tumors that have HER2 gene mutations. The drug aims to block the abnormal HER2 protein and stop cancer growth. Participants take a 20 mg tablet daily in 3-week cycles u…

This study is testing the drug T-DXd (Enhertu) in 100 adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. The goal is to see how well the drug works in real-world settings, including how many patients respond and …

This phase 3 trial compares a new drug, velzatinib, to the standard drug imatinib in 800 people with advanced gastrointestinal stromal tumors (GIST) that have spread or cannot be removed by surgery. The goal is to see if velzatinib can delay tumor growth better than imatinib. Par…

This study tests whether adding an experimental drug (KQB198) to the standard cancer pill imatinib can shrink or control advanced gastrointestinal stromal tumors (GIST). About 46 adults with a specific gene mutation (KIT or PDGFRA) will receive the combination. The goal is to see…

This study tests a drug called FORE8394 (plixorafenib) in people aged 10 and older whose cancers have specific BRAF gene changes. The goal is to see if the drug can shrink tumors or slow their growth. About 254 participants with advanced solid tumors or brain tumors will take the…

This phase 3 trial is testing whether the experimental drug olverembatinib can slow or stop tumor growth in people with a rare form of gastrointestinal stromal tumor (GIST) that lacks a key enzyme called SDH. The study enrolls adults whose cancer has progressed after at least one…

This study tests a new drug called DCC-3116 combined with other cancer treatments for people with advanced GIST, a type of stomach or intestinal cancer. The goal is to find safe doses and see if the combination shrinks tumors. About 94 adults whose cancer has worsened after stand…

This early-stage study tests the safety of an experimental drug called DCC-2618 in 10 people with advanced gastrointestinal stromal tumor (GIST) that has not responded to or cannot tolerate at least three prior treatments. The main goal is to see what side effects occur. This is …

This expanded access program provides bezuclastinib, an investigational drug, combined with sunitinib for adults with advanced gastrointestinal stromal tumors (GIST) who cannot tolerate or have progressed on imatinib. The goal is to offer a potential treatment when no satisfactor…

This study tests whether adding the experimental drug CGT9486 to the standard drug sunitinib helps people with advanced GIST live longer without their cancer growing. About 482 adults with GIST that cannot be removed by surgery or has spread will take part. The goal is to see if …

This study tests an experimental drug called NB003 in people with advanced GIST that has worsened after standard treatments. The trial has two parts: one compares NB003 to the approved drug regorafenib as a third-line therapy, and the other tests NB003 alone as a second-line ther…

This early-phase study tests adding fampridine to standard imatinib (Gleevec) in 18 adults with a specific type of GIST tumor. Participants take the drugs for at least 2 months before surgery to find the safest dose and see if the combination shrinks tumors. The goal is to improv…

This phase 2 study tests the drug pemigatinib in 24 people with advanced SDH-deficient GIST, a rare stomach tumor that has spread and cannot be removed by surgery. The goal is to see if the drug can shrink tumors and how well patients tolerate it. Participants take a daily pill, …

This study tests whether combining two drugs—regorafenib (a targeted therapy) and envafolimab (an immunotherapy)—can help people with advanced GIST that has a specific gene change (KIT exon 17 mutation) and has stopped responding to standard treatments. About 100 adults will be r…

This early-stage trial is testing an oral drug called HQP1351 in about 100 people with advanced gastrointestinal stromal tumors (GIST) or other solid tumors. The main goal is to find a safe dose and see how the body handles the drug. Participants take the pill every other day for…

This phase 2 trial tests an oral form of paclitaxel (Liporaxel) in 28 adults with advanced gastrointestinal stromal tumors (GIST) that no longer respond to three standard drugs: imatinib, sunitinib, and regorafenib. The study focuses on patients whose tumors have low levels of a …

This phase 2 trial tests a combination of two drugs—rivoceranib and paclitaxel—in 48 adults with advanced gastrointestinal stromal tumors (GIST) that have a specific protein marker (high P-glycoprotein) and have stopped responding to three standard treatments. The goal is to see …

This study tests the drug temozolomide in people with a rare type of advanced stomach cancer called SDH-deficient GIST. About 29 adults will receive the drug to see if it shrinks tumors and is safe. The goal is to control the disease, not cure it.

This study tests the drug lenvatinib in 48 adults with advanced gastrointestinal stromal tumors (GIST) that have stopped responding to three standard treatments. Participants take lenvatinib capsules daily, and researchers will measure how many patients have their disease control…

This study compares two endoscopic procedures—EFTR and STER—for removing small gastric GIST tumors (1.0–3.5 cm). About 136 adults from Hong Kong, mainland China, India, and Japan will be randomly assigned to one method. The goal is to see which technique achieves complete tumor r…

This study looks at how safe robotic surgery is for removing gastrointestinal stromal tumors (GISTs) located in hard-to-reach areas of the stomach. About 182 adults with small to medium tumors (2-5 cm) will have the robotic procedure. Researchers will track how many patients stay…

This study tests a new drug called DCC-3009, alone or with other cancer treatments, for people with advanced gastrointestinal stromal tumor (GIST) that has stopped responding to standard therapy. About 120 participants will receive the drug in 28-day cycles for up to 2 years. The…

This early-phase trial is testing a new combination of two drugs—ziftomenib and imatinib—in adults with advanced gastrointestinal stromal tumors (GIST) that have stopped responding to imatinib alone. The study will first find a safe dose, then check if the combination can shrink …

This early-stage trial tests a new drug called NN3201 in people with advanced cancers that have a specific marker called c-Kit. The drug is designed to deliver a chemotherapy agent directly to cancer cells, potentially killing them while sparing healthy tissue. The study will enr…

This phase 2 trial tests whether DNA changes in the KIT gene can predict how well patients with advanced gastrointestinal stromal tumor (GIST) respond to two standard drugs, sunitinib and regorafenib. About 48 adults whose GIST has worsened on imatinib will receive the drugs in s…

This study compares two ways to take tissue samples from stomach tumors to see which one gives a more accurate diagnosis. About 96 adults with stomach tumors at least 15mm in size will be randomly assigned to one of the two methods. The goal is to improve how doctors diagnose the…

This study tests whether regularly checking imatinib levels in the blood can reduce side effects and improve quality of life for people with gastrointestinal stromal tumors (GIST). About 28 adults starting or recently starting imatinib will participate. The goal is to see if this…

This study tests a surgical technique called a jejunal pouch in 26 adults who need their entire stomach removed due to cancer or a high-risk gene mutation. The pouch is created from a section of the small intestine to replace the stomach's reservoir function. The goal is to reduc…

This study tests a new two-tooth clip designed to help doctors remove gastrointestinal stromal tumors (GIST) from the stomach during endoscopy. The clip holds the tumor steady, making it easier to cut away. The trial will compare this method to standard techniques in 60 adults. T…

This study is for Black adults newly diagnosed with gastrointestinal cancer. It focuses on ensuring patients receive proper biomarker testing and evidence-based care, helping them find and join clinical trials if they choose, and providing easy-to-understand information about the…

This study follows 400 people aged 6 and older who have a rare stomach cancer called GIST. Researchers will collect tumor tissue during surgery and study it in the lab to learn more about the disease. Participants are monitored every 6 to 12 months for up to 10 years before surge…

This study looks at whether measuring the amount of certain targeted cancer drugs in the blood can help find the best dose for each patient. It involves adults with advanced digestive cancers like colorectal, liver, and stomach tumors who are already taking these medications. By …

This study is a patient registry for people diagnosed with gastrointestinal stromal tumor (GIST). It collects detailed information about participants' health, treatments, and outcomes over time. The goal is to help researchers better understand the disease, track how patients far…

This study explores whether a blood test that detects circulating tumor DNA (ctDNA) can help doctors personalize treatment for people with five types of advanced cancer: non-small cell lung cancer, gastrointestinal stromal tumors, colorectal cancer, biliary tract cancer, and ovar…

This study is building a huge registry of information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. Researchers will use this resource to study what causes cancer and how to better prevent, detect, and treat it. The re…

This study aims to discover new genes that may cause certain cancers to run in families. Researchers will collect blood samples and health information from 1,500 people in families where multiple members have had cancer, especially childhood cancers. The goal is to build a regist…

This study is building a large database of 15,000 patients with esophageal or gastric cancers in France. Researchers will look back at medical records to see how patients fared after surgery, focusing on how long they stayed cancer-free. The goal is to learn more about survival, …

This study follows 330 adults with advanced or metastatic GIST who have been on targeted therapy (TKIs) for at least 2 years. Researchers will track quality of life, treatment side effects, and financial burdens over up to 10 years. The goal is to better understand the real-world…

This study looks at whether follow-up care for people with rare tumors can be done just as well by a nurse remotely as by a doctor in person. About 88 adults recently diagnosed with a rare tumor will be randomly assigned to either in-person doctor visits or remote nurse check-ins…

This study at Stanford University collects tissue and blood samples from 100 adults with or at high inherited risk for stomach, esophageal, or related cancers. Researchers aim to understand how genes and proteins contribute to cancer development. The study does not test any treat…

This study collects and stores tissue and blood samples from people with stomach, esophageal, pancreatic, liver, and other gastrointestinal cancers. The goal is to build a large database of samples and medical information to help researchers understand these cancers better. Parti…